Key Highlights
- Moderna began a Phase 1 clinical trial of mRNA-1469, its investigational vaccine against Bundibugyo ebolavirus, after receiving Health Canada authorization.
- The trial will enroll approximately 80 healthy adult participants across three sites in Canada to evaluate safety, tolerability and immune response.
- The program is part of an expanded collaboration with the Coalition for Epidemic Preparedness Innovations, which has committed up to 50 million dollars to support preclinical testing and the Phase 1 trial.
- The outbreak driving the trial has become the second-largest Ebola outbreak on record, with more than 3,000 confirmed cases and more than 1,400 deaths in the Democratic Republic of Congo.
A Rapid Advance Into Human Testing for an Unaddressed Ebola Strain
Moderna (NASDAQ:MRNA) announced that the first participants have been vaccinated in a Phase 1 clinical trial evaluating mRNA-1469, its investigational mRNA vaccine designed to prevent disease caused by Bundibugyo ebolavirus, following authorization from Health Canada. The vaccine candidate uses the same mRNA platform technology that enabled Moderna's rapid development and global deployment of its COVID-19 vaccine, applied here to a filovirus strain for which no licensed vaccine currently exists.
Moderna's chief executive officer described the vaccination of the first trial participants as an important milestone in advancing a vaccine candidate against a strain of Ebola virus disease that has no approved prevention option, crediting the collaborative effort involving the trial's funding partner, Canadian health authorities, investigators and study participants. The Phase 1 study is being conducted at three sites in Canada and is expected to enroll approximately 80 healthy adult participants to assess the vaccine's safety, tolerability and ability to generate an immune response.
Partnership Funding Supports Accelerated Development Timeline
The vaccine program is advancing under Moderna's expanded strategic collaboration with the Coalition for Epidemic Preparedness Innovations, which has committed up to 50 million dollars to support preclinical testing and the current Phase 1 trial. This funding arrangement also supports parallel manufacturing of additional clinical trial doses alongside early-stage development, an approach designed to allow larger Phase 2 and Phase 3 studies to begin quickly should Phase 1 results support continued development.
The coalition's chief executive characterized the rapid progression into human trials as a major step in addressing what he described as a fast-growing epidemic, noting that case numbers are rising more quickly than they did during the 2014 to 2016 West Africa Ebola epidemic, which remains the largest outbreak on record. This urgency framing underscores the compressed development timeline Moderna and its partners are pursuing relative to more typical vaccine development programs.
Outbreak Scale Underscores the Public Health Stakes
The Bundibugyo strain is driving an active outbreak in the Democratic Republic of Congo that has become the second-largest Ebola outbreak on record, with more than 3,000 confirmed cases and more than 1,400 deaths reported, and figures continuing to climb. The World Health Organization and Africa CDC have each declared the outbreak a public health emergency under their respective frameworks, formal designations that typically mobilize additional international resources and coordination toward response efforts.
While vaccines already exist for the more commonly addressed Zaire ebolavirus strain, no vaccine is currently approved specifically for Bundibugyo ebolavirus, leaving a meaningful gap in available prevention tools for the strain responsible for the current outbreak. Should mRNA-1469 progress successfully through subsequent clinical trial phases and eventual regulatory review, Moderna has committed to making at least 500,000 doses available to low- and middle-income countries at access pricing as part of its agreement with the coalition, a commitment structured to address affordability and access concerns common to outbreak-response vaccines.
Conclusion
Moderna's initiation of human trials for mRNA-1469 represents a rapid application of its mRNA vaccine platform to an outbreak that has already surpassed most historical Ebola events in scale and pace of spread. The combination of coalition funding, parallel manufacturing preparation and a defined access commitment for lower-income countries reflects a development approach oriented toward speed without abandoning affordability considerations. Whether this Phase 1 trial generates sufficiently promising safety and immunogenicity data to support accelerated progression into larger studies is likely to significantly influence how quickly a vaccine option becomes available for a strain that currently has none.






Please wait processing your request...